All News
Obintuzumab in Lupus Nephritis
d
EurekAlert
In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney con
Read Article
ACR Convergence Preview (11.10.2023)
Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.
Read Article
Rheumatoid Synovium Characterized by Six Cell Type Phenotypes
Research work from the Accelerating Medicines Partnership (AMP: RA/SLE) Network, was published in Nature and more specifically characterizes RA synovium into several cell-type abundance phenotypes (CTAPs). Could CTAPs known disease features or more effective future therapies?
Read Article
Arthritis Increased Amongst US Veterans
d
CDC
A recent CDC reports estimates that in 2019–2021, 21% of U.S. adults (53.2 million) have physician diagnosed arthritis. Now, an updated report shows a larger number (~33%) of U.S. veterans having diagnosed arthritis. Compared to nonveterans, this prevalence was double in men, and 60% higher in women.
Read Article
Dr. del Carmen Zamora-Medina listed several reasons why rheum patients may seek #abortion: teratogenic meds, comorbidities, high disease activity, increased APOs, &women focused reasons. #ACR23 @GlobalSummit #ReproductiveRights @Rheumnow https://t.co/CaH9GVfVvY
TheDaoIndex KDAO2011 ( View Tweet)
On the way to #ACR23! Would love to meet y'all IRL, please come say hello!
Will be at FIT session, trainee posters (see pics!), moderating Going Viral w/Podcasts, & reporting for @RheumNow
Also, please come watch Knowldege Bowl!! (co-hosting w/@MarkCHwang & @NamrataRheum) https://t.co/jhUj8XASex
Mike Putman EBRheum ( View Tweet)
Such contrast to the US!
Mexico’s legislature has de-criminalized abortion, making legal and safe abortions avail to rheum pts #ACR23 #GlobalSummit @Rheumnow @CuoghiE https://t.co/xAezGyav0E
TheDaoIndex KDAO2011 ( View Tweet)
There are lots of reasons why First Nations people might have difficulties with rheumatology care (especially those in remote communities).
Population realities
Healthcare access
Medication access
All have a very real impact on the quality of care we deliver.
#ACR23 @RheumNow https://t.co/qDBsQRWjk9
David Liew drdavidliew ( View Tweet)
What did they do in Canada to improve the care for their patients of Indigenous background?
Practical but strategic approach to healthcare service improvement - that lead to real benefits.
#ACR23 @RheumNow https://t.co/VlGW3KBFCj
David Liew drdavidliew ( View Tweet)
X-Rays Questioned for Diagnosing Early Rheumatoid Arthritis
Routine hand and foot radiographs in more than 700 patients being evaluated for RA made almost no difference in diagnosing the condition nor in predicting its course, Dutch researchers said.
https://t.co/afU0Td7GOA https://t.co/UCOmBQtpE5
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
Dr. Iyer - factors driving inequity in the access of essential medicines esp. in low to middle-income countries:
💠availability
💠affordability
💠accessibility
💠acceptability
#ACR23 @RheumNow @rheumarhyme https://t.co/eIvOAjg31H
sheila ( View Tweet)
Inequities in Medical Care Delivery:
👉>80% of people live in low/middle income places
👉2 billion people are unable to access meds and healthcare services
👉Availability, accessibility, affordability, acceptability are the 4 barriers
Dr. J Iyer #ACR23 @RheumNow #GlobalSummit https://t.co/u21NTAYBpY
TheDaoIndex KDAO2011 ( View Tweet)
Big Pharma – Pay attention! When developing new therapeutics, consider delivery, cost, climate sensitivity and sustainability #GlobalSummit @ACRheum @rheumnow #ACR23 https://t.co/ThqnTI3SNm
TheDaoIndex KDAO2011 ( View Tweet)
Opportunities to address healthcare inequities: generics/biosimilars, fair pricing, and inclusive business models. #GlobalSummit @RheumNow #ACR23 @ACRheum https://t.co/ynJWWcCqWo
TheDaoIndex KDAO2011 ( View Tweet)
Retrospective study(2016-2019) of referred newly, suspected (#RA) pts found no value in initial Xrays. Only 32/724 patients (4.4%) had RA like erosions, with Erosions leading to a Dx in only 2 pts (0.3%) & changed prognostic classification in 3 pts (0.4%) https://t.co/fi48WiBgIc https://t.co/skObArXYr6
Dr. John Cush RheumNow ( View Tweet)
Orthopedic cohort study of 274,403 pts (180K females, 94K males; mean age=55). The risk of future TKA was signif greater in pts w/ combination of Depression+Obesity group (11.9%); compared to Controls (8.3%), obese (10.2%) or Depression (7.8%) https://t.co/dltVS0Y6PY https://t.co/REgO5tjEUv
Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY: Your choice of a biologic in SpA patients is mostly influenced by? Respond here>> https://t.co/AtX4vZBvIT https://t.co/CgzROe8irB
Dr. John Cush RheumNow ( View Tweet)
Introducing RheumNow's #ACR23 faculty! They'll be covering ACR this weekend with valuable tweets, articles, videos and more. Follow us for real time updates. https://t.co/c9jla43lqw
Dr. John Cush RheumNow ( View Tweet)
QD Clinics - Neighbor Consults
Your neighbor has a Swollen RPIP4.
QD Clinics are sponsored by RheumNows Coverage of #ACR23 live from San Diego
https://t.co/ZXNalfiVFv https://t.co/TAxpVyowF5
Dr. John Cush RheumNow ( View Tweet)